**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**



**FORM 8-K**



**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 14, 2021 (May 13, 2021)**



**Repare Therapeutics Inc.**

**(Exact Name of Registrant as Specified in Its Charter)**



|  |  |  |
| --- | --- | --- |
| **Québec** | **001-39335** | **Not applicable** |
| **(State or Other Jurisdiction** | **(Commission** | **(I.R.S. Employer** |
| **of Incorporation)** | **File Number)** | **Identification No.)** |
| **7210 Frederick-Banting, Suite 100** |  |  |
| **St-Laurent, Québec, Canada** |  | **H4S 2A1** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

**Registrant’s Telephone Number, Including Area Code: (857) 412-7018**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report.)**



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

* Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
* Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
* Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
* Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Title of each class** | | **Trading Symbol** | | **Name of each exchange** |  |
| **on which registered** |  |
| **Common shares, no par value** |  | **RPTX** |  | **The Nasdaq Stock Market LLC** |  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



**Item 5.07** **Submission of Matters to a Vote of Security Holders.**

On May 13, 2021, Repare Therapeutics Inc., a corporation governed by the *Business Corporations Act* (Québec) (the “Company”) held its Annual Meeting of Shareholders (“Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the two proposals set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 1, 2021.

**Proposal 1 – Election of Directors**

Jerel Davis, Ph.D., Todd Foley and Ann D. Rhoads were each elected to serve as a Class I director of the Company’s Board of Directors until the 2024

Annual Meeting of Shareholders and until his or her successor is duly elected or until his or her earlier resignation or removal, by the following votes:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Nominee** | | **Votes For** | | **Votes Withheld** | | **Broker Non-Votes** |
| Jerel Davis, Ph.D. |  | 29,759,115 |  | 3,122,873 |  | 1,364,632 |
| Todd Foley | | 29,731,331 |  | 3,150,657 |  | 1,364,632 |
| Ann D. Rhoads | | 32,845,796 |  | 36,192 |  | 1,364,632 |

**Proposal 2 – Appointment of Independent Registered Public Accounting Firm**

The shareholders approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending

December 31, 2021, by the following votes:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Votes For** | | **Votes Against** | | **Votes Withheld** |
| 34,244,251 |  | 2,289 |  | 80 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPARE THERAPEUTICS INC.**

By: /s/ Lloyd M. Segal



Lloyd M. Segal

President and Chief Executive Officer

Dated: May 14, 2021